You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Public Rights-of-Way Assessment Instrumentation to Determine Accessibility

    SBC: BENEFICIAL DESIGNS INC            Topic: 081FH2

    City planners and engineers need detailed assessments of public rights-of-way to evaluate existing conditions, determine compliance with draft accessibility guidelines, and plan reconstruction projects. Current assessment methods are inadequate and inefficient due to the time and resources required. This project will develop an automated public rights-of-way assessment process and the measuremen ...

    SBIR Phase II 2010 Department of Transportation
  2. Not Available

    SBC: STEMINA BIOMARKER DISCOVERY, INC            Topic: NCI

    Brain tumor stem cells (BTSCs) are a subset population within tumors that are widely believed to be responsible for tumor recurrence, due to their ability to self-renew, differentiate, migrate, and initiate tumor propagation. Given these unique features, the selective targeting of BTSCs with novel therapies may prevent tumor recurrence. Stemina will progress efforts to determine BTSC biomark ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Product Development of a Brain Tumor Perfusion Imaging Technology

    SBC: IMAGING BIOMETRICS LLC            Topic: NCI

    DESCRIPTION (provided by applicant): The goal of this Phase II SBIR proposal is to expand upon the research and development efforts, begun in Phase I, with new enhancements and product offerings, while also taking the initial steps to position the Company for a multi-center clinical trial, planned for Phase III. Phase I efforts have led to the development and commercialization of the Company's fir ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Structure-Stabilized GPCRs for Functional Analysis and Crystallography

    SBC: LUCIGEN CORPORATION            Topic: NIMH

    DESCRIPTION (provided by applicant): G-Protein coupled receptors (GPCRs) are a large family of proteins expressed on the surface of eukaryotic cells. They are the major pathway for transducing extracellular signals into a diversity of intracellular responses. Because of their accessibility and physiological significance, GPCRs are the targets of approximately 30-50% of drugs on the market. GPCRs a ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Novel systems for mammalian expression, integration, and knockout of previously '

    SBC: LUCIGEN CORPORATION            Topic: NIGMS

    DESCRIPTION (provided by applicant): The goal of this Phase II proposal is to develop systems for transient, stable, and transgenic expression of nearly any DNA sequence, particularly those that are impossible to clone into current vectors. Primary targets include genes containing long trinucleotide repeats, toxic ORFs, and very AT-rich regions of up to 50 kb. The systems will be based on a no ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  6. NanoMedex Propofol Microemulsion (Microfol): Preclinical Studies to FDA IND App.

    SBC: NANOMEDEX, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Propofol is the largest selling, intravenous general anesthetic that may have several adverse effects due to its lipophilicity and need to be formulated in Intralipid. We propose to develop a patented microemulsion of propofol in which the lipophilicity of propofol is leveraged to serve dual roles as both the lipid oil core of the microemulsion and a pharmacod ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Polymer Coatings to Prevent Biofilms on Urinary Stents and Catheters

    SBC: Nerites Corporation            Topic: NIDDK

    DESCRIPTION (provided by applicant): Novel Polymer Coatings to Prevent Biofilms on Urinary Stents and Catheters Bacterial infection and subsequent encrustation of urinary stents and catheters is a persistent problem in clinical urology and leads to significant patient morbidity and mortality. Most implanted stents become infected at some point, requiring retrieval and re-implantation if the initia ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  8. The Swept Field Confocal Microscope

    SBC: Prairie Technologies, Inc.            Topic: NIMH

    DESCRIPTION (provided by applicant): A primary goal in neuroscience is to understand at a mechanistic level the functioning of neuronal networks with specific behaviors. This involves in general, the anatomical connectivity among the various types of neurons within the local network, the physiological properties of these cells, and the spatiotemporal firing signals of the neurons within the circui ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel Multiplexed Assay for Rapid Antibody Screening

    SBC: PRIMORIGEN BIOSCIENCES INC.            Topic: NCRR

    DESCRIPTION (provided by applicant): Primorigen Biosciences will use Phase II SBIR funds to accelerate and expand the development of new regenerative medicine cell therapies by developing a novel high throughput, low cost protein quantification system for characterizing pancreatic 2 cell and islet cell differentiation. Primorigen successfully confirmed the technical feasibility of this proposal by ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  10. New Multiplexed Quantitative Detection of Pluripotency and Germ Layer Proteins

    SBC: PRIMORIGEN BIOSCIENCES INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Primorigen Biosciences will use Phase II SBIR funds to accelerate and expand the development of new regenerative medicine cell therapies by developing a novel high throughput, low cost protein quantification system for characterizing pluripotent cell lines and early germ layer differentiation. Primorigen successfully confirmed the technical feasibility of this ...

    SBIR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government